Richard C. Breeden - 15 Feb 2023 Form 4 Insider Report for STERIS plc (STE)

Role
Director
Signature
/s/ Ronald E. Snyder, Authorized Representative under Power of Attorney
Issuer symbol
STE
Transactions as of
15 Feb 2023
Net transactions value
+$204,535
Form type
4
Filing time
17 Feb 2023, 15:35:30 UTC
Previous filing
05 Aug 2022
Next filing
16 May 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STE Ordinary Shares Options Exercise $204,535 +4,657 +12% $43.92 42,837 15 Feb 2023 Direct
holding STE Ordinary Shares 27,242 15 Feb 2023 See Footnotes Below F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STE Director Stock Option (right to buy) Options Exercise -4,657 -100% 0 15 Feb 2023 Ordinary Shares 4,657 $43.92 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Richard C. Breeden is the managing member of Breeden Capital Partners LLC, and managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC (the "General Partner") is in turn the general partner of Breeden Partners L.P. (the "Fund").
F2 Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares. Mr. Breeden disclaims beneficial ownership over 1,358 of these shares held by Breeden Partnership LLP.
F3 This option to purchase 4,657 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 4,657 ordinary shares for $43.92 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option.